Publications by authors named "Melgosa-Ramos F"
Moderate-to-severe hidradenitis suppurativa (HS) is a debilitating disease that often requires biological therapy. Despite the effectiveness of approved doses, some patients experience partial or loss of response over time, leading to the need for dose intensification. This retrospective multicentre study aimed to identify predictors of biological therapy intensification in HS patients.
View Article and Find Full Text PDFArticle Synopsis
- - A study evaluated the effectiveness and safety of dupilumab for treating bullous pemphigoid in elderly patients, with a focus on those who typically have other health issues that make standard treatments unsuitable.
- - The results showed that 53.4% of patients achieved complete remission within 4 weeks and 95.7% by week 52, with a significant reduction in itchiness and a dramatic decrease in the need for corticosteroids.
- - The treatment was found to be safe, with most adverse events being mild, and factors like shorter disease duration and exclusive skin involvement were linked to better treatment responses.
Article Synopsis
- - A study was conducted on 322 patients with hidradenitis suppurativa (HS) at a Spanish hospital to find out which factors indicate more severe cases of HS and may require aggressive treatment.
- - Results showed that longer diagnostic delays, conditions like acne conglobata, certain cardiovascular risk factors, and perianal or truncal involvement were linked to more severe HS.
- - Interestingly, psychiatric comorbidities did not influence HS severity, while being female and having a family history of HS were associated with an earlier onset of the disease.
Tildrakizumab is an IL-23-inhibitor that has been approved to treat plaque psoriasis. However, few reports have become available on its efficacy profile in the real-world. Our objective was to study the mid-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the Spanish routine clinical practice setting.
View Article and Find Full Text PDFArticle Synopsis
- Bullous pemphigoid (BP) is a common autoimmune blistering condition usually affecting older adults with various health issues, traditionally treated with corticosteroids, which have numerous side-effects.* -
- A study assessed the use of omalizumab, an IgE-targeting monoclonal antibody, for treating BP in patients who had previously used other therapies, finding that 83% of patients responded to the treatment.* -
- The results showed that omalizumab was well-tolerated with no reported side-effects, highlighting its potential as a safer and effective alternative for BP treatment compared to conventional therapies.*
This was an observational and retrospective multicentre study conducted on adolescents and adults diagnosed with moderate-to-severe atopic dermatitis (AD) and treated with upadacitinib. Disease severity was measured by Eczema Area and Severity Index (EASI), validated investigator global assessment for AD and pruritus Numerical Rating Scale (NRS) at baseline and Weeks 4, 16, 24 and 52 (when available). Twenty-one patients were included.
View Article and Find Full Text PDFDistinguishing between congenital and infantile hemangiomas is challenging, but essential for appropriate treatment. The immunohistochemical marker glucose transporter type 1 is helpful, but biopsies are uncommon in this setting. The aim of this retrospective study was to describe and compare epidemiological, clinical, and treatment characteristics of congenital and infantile hemangiomas diagnosed at a tertiary care hospital over 3 years.
View Article and Find Full Text PDF